AiHua Shen

840 total citations
17 papers, 701 citations indexed

About

AiHua Shen is a scholar working on Molecular Biology, Physiology and Pathology and Forensic Medicine. According to data from OpenAlex, AiHua Shen has authored 17 papers receiving a total of 701 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Physiology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in AiHua Shen's work include Calcium signaling and nucleotide metabolism (5 papers), Hearing, Cochlea, Tinnitus, Genetics (4 papers) and Sirtuins and Resveratrol in Medicine (4 papers). AiHua Shen is often cited by papers focused on Calcium signaling and nucleotide metabolism (5 papers), Hearing, Cochlea, Tinnitus, Genetics (4 papers) and Sirtuins and Resveratrol in Medicine (4 papers). AiHua Shen collaborates with scholars based in South Korea, China and United States. AiHua Shen's co-authors include Hong‐Seob So, Gi‐Su Oh, Dipendra Khadka, Arpana Pandit, Hyungjin Kim, Seong‐Kyu Choe, Sei‐Hoon Yang, Tae Hwan Kwak, Raekil Park and Hyung‐Jin Kim and has published in prestigious journals such as The Journal of Immunology, Biochemical and Biophysical Research Communications and Kidney International.

In The Last Decade

AiHua Shen

17 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
AiHua Shen South Korea 13 259 220 123 91 75 17 701
Gerald Wölkart Austria 18 126 0.5× 258 1.2× 58 0.5× 40 0.4× 25 0.3× 40 961
Nathan Robbins United States 16 52 0.2× 274 1.2× 181 1.5× 35 0.4× 12 0.2× 34 778
Srinivas M. Tipparaju United States 18 127 0.5× 629 2.9× 10 0.1× 79 0.9× 25 0.3× 50 1.3k
Yuka Kohda Japan 14 175 0.7× 150 0.7× 15 0.1× 42 0.5× 57 0.8× 35 586
Xin Qin China 14 24 0.1× 323 1.5× 61 0.5× 49 0.5× 18 0.2× 37 826
Matem Tunçdemi̇r Türkiye 16 108 0.4× 179 0.8× 5 0.0× 50 0.5× 35 0.5× 45 750
Hitesh Soni United States 15 91 0.4× 244 1.1× 63 0.5× 26 0.3× 21 0.3× 35 538
Mingjun Gu China 17 82 0.3× 607 2.8× 14 0.1× 84 0.9× 15 0.2× 40 1.1k
Lingzhi Zhang China 15 101 0.4× 210 1.0× 19 0.2× 33 0.4× 31 0.4× 58 588
Emmanuelle Plée‐Gautier France 13 57 0.2× 172 0.8× 164 1.3× 32 0.4× 30 0.4× 22 711

Countries citing papers authored by AiHua Shen

Since Specialization
Citations

This map shows the geographic impact of AiHua Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AiHua Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AiHua Shen more than expected).

Fields of papers citing papers by AiHua Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by AiHua Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AiHua Shen. The network helps show where AiHua Shen may publish in the future.

Co-authorship network of co-authors of AiHua Shen

This figure shows the co-authorship network connecting the top 25 collaborators of AiHua Shen. A scholar is included among the top collaborators of AiHua Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AiHua Shen. AiHua Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shen, AiHua, et al.. (2025). The interplay between DNA damage response and mitochondrial dysfunction in radiotherapy. Frontiers in Oncology. 15. 1642100–1642100. 1 indexed citations
2.
Wang, Qi, Shuhua Yang, AiHua Shen, et al.. (2024). Effects of a novel HDAC6-selective inhibitor’s radiosensitization on cancer cells. Molecular Biology Reports. 51(1). 1151–1151. 2 indexed citations
3.
Pan, Dong, et al.. (2024). When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity. International Journal of Cancer. 155(3). 384–399. 9 indexed citations
4.
Pan, Dong, Rong Li, AiHua Shen, et al.. (2021). miR-29b-3p Increases Radiosensitivity in Stemness Cancer Cells via Modulating Oncogenes Axis. Frontiers in Cell and Developmental Biology. 9. 741074–741074. 13 indexed citations
5.
Kim, Hyungjin, Gi‐Su Oh, Seunghoon Lee, et al.. (2019). Augmentation of cellular NAD+ by NQO1 enzymatic action improves age‐related hearing impairment. Aging Cell. 18(5). e13016–e13016. 37 indexed citations
6.
Khadka, Dipendra, Hyungjin Kim, Gi‐Su Oh, et al.. (2018). Augmentation of NAD+ levels by enzymatic action of NAD(P)H quinone oxidoreductase 1 attenuates adriamycin-induced cardiac dysfunction in mice. Journal of Molecular and Cellular Cardiology. 124. 45–57. 27 indexed citations
7.
Shen, AiHua, Hyung‐Jin Kim, Gi‐Su Oh, et al.. (2018). Pharmacological stimulation of NQO1 decreases NADPH levels and ameliorates acute pancreatitis in mice. Cell Death and Disease. 10(1). 5–5. 28 indexed citations
8.
Oh, Gi‐Su, Su‐Bin Lee, Hyungjin Kim, et al.. (2016). Increased Cellular NAD+Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberculosis & respiratory diseases. 79(4). 257–257. 22 indexed citations
9.
Oh, Gi‐Su, Hyungjin Kim, AiHua Shen, et al.. (2016). New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity. BioMed Research International. 2016. 1–12. 38 indexed citations
10.
Kim, Hyungjin, Gi‐Su Oh, AiHua Shen, et al.. (2015). Nicotinamide adenine dinucleotide: An essential factor in preserving hearing in cisplatin-induced ototoxicity. Hearing Research. 326. 30–39. 7 indexed citations
11.
Pandit, Arpana, Hyung‐Jin Kim, Gi‐Su Oh, et al.. (2015). Dunnione ameliorates cisplatin-induced small intestinal damage by modulating NAD+ metabolism. Biochemical and Biophysical Research Communications. 467(4). 697–703. 22 indexed citations
12.
Kim, Hyung‐Jin, Arpana Pandit, Gi‐Su Oh, et al.. (2015). Dunnione ameliorates cisplatin ototoxicity through modulation of NAD + metabolism. Hearing Research. 333. 235–246. 19 indexed citations
13.
Kim, Hyung‐Jin, Gi‐Su Oh, AiHua Shen, et al.. (2014). Capsaicin Ameliorates Cisplatin-Induced Renal Injury through Induction of Heme Oxygenase-1. Molecules and Cells. 37(3). 234–240. 44 indexed citations
14.
Oh, Gi‐Su, Hyungjin Kim, AiHua Shen, et al.. (2014). Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies. PubMed. 12(2). 55–55. 183 indexed citations
15.
Oh, Gi‐Su, Hyungjin Kim, AiHua Shen, et al.. (2013). Pharmacological activation of NQO1 increases NAD+ levels and attenuates cisplatin-mediated acute kidney injury in mice. Kidney International. 85(3). 547–560. 130 indexed citations
16.
Lee, Jeong‐Han, Channy Park, Se-Jin Kim, et al.. (2013). Different uptake of gentamicin through TRPV1 and TRPV4 channels determines cochlear hair cell vulnerability. Experimental & Molecular Medicine. 45(3). e12–e12. 51 indexed citations
17.
Oh, Gi‐Su, Hyungjin Kim, AiHua Shen, et al.. (2010). Activation of Lipopolysaccharide–TLR4 Signaling Accelerates the Ototoxic Potential of Cisplatin in Mice. The Journal of Immunology. 186(2). 1140–1150. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026